Geriatric Medicines Market
Geriatric Medicines Market Report By Therapeutic Category (Analgesic, Anti-Hypertensive, Anti-Diabetic, Anticoagulant, Anti-Depressant), By Condition (Cardiovascular Ailments, Arthritis, Diabetes, Neurological Disorders), By Distribution Channel & Regional Forecast 2021-2031
Geriatric Medicines Market Outlook
Fact.MR, a market research and competitive intelligence provider, states that the sales of geriatric medicines will reach US$ 768 Mn by the end of 2021. As per the report, geriatric medicines for cardiovascular ailments will account for 45% revenue until 2031. By the end of the forthcoming decade, the global market for geriatric medicines will likely surpass US$ 1.5 Bn.
Key Points Covered in Geriatric Medicines Industry Analysis
- Market estimates and forecast 2016-2031
- Key drivers and restraints impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Geriatric Medicines Market and How to Navigate
- Recommendation on Key Winning Strategies
Geriatric Medicines Consumption Analysis 2016-2020 in Comparison to Future Outlook 2021-2031
As per Fact.MR’s report, from 2016 to 2020, the sales of geriatric medicines expanded at a CAGR of 5.5%. Continuous research is leading to production of newer medicines that are influencing the sales of geriatric medicines industry positively.
Amid the COVID-19 pandemic, growth prospects inclined massively, with prominent pharmaceutical giants collaborating to develop effective anti-COVID-19 orally and subcutaneously injectable drug candidates. Presently, over 2 billion people have been inoculated against the novel coronavirus.
Future growth prospects will majorly depend on efforts to curb the spread of infectious diseases and pandemics, as well as mitigation of the impact of surging cardiovascular ailments. Thus, due to the aforementioned factors, the sales of geriatric medicines is expected to register a CAGR of 7% from 2021 to 2031.
Increasing Geriatric Population to Broaden Prospects of Geriatric Medicines Industry?
There is a substantial uptick in the geriatric population worldwide. The World Health Organization (WHO) concludes that people over the age of 65 constitute the fastest-growing segment. By 2050, it is predicted that the global geriatric population shall reach 22%, reaching a figure of 2 billion.
This, in turn, has led to an increase in the incidences of chronic diseases such as cancer, diabetes, neurological ailments and respiratory problems. Thus, increasing geriatric population across the globe is anticipated to broaden prospects for geriatric medicines in the future.
Increasing government support for the elderly with respect to their health, safety and nursing care has also increased. Furthermore, growing prevalence of quality geriatric care management systems is set to provide traction to the market for geriatric medicines in the forecast period.
Avail customized purchase options for your needs
How has COVID-19 Impacted Geriatric Medicines Industry?
The ongoing coronavirus pandemic has led to significant disruptions in supply chains across several businesses. Nationwide lockdowns have led to production cuts as manufacturing plants operate at half of their original capacity. It is evident from the statistics that the geriatric population is the most vulnerable to infection from the COVID-19 virus.
As of October 2021, over 240 million active cases have been recorded, while vaccine dosages amount to over 6 billion. However, the quest to discover an orally consumable drug still persists. Recently, in September 2021, pharmaceutical player Merck & Co. Inc. announced new clinical trials for their experimental oral anti-viral drugs, in collaboration with Pfizer Inc.
The results of these trials were published in October. The drug under question is Molnupiravir which has been proven to reduce hospitalization rates by 50% amongst mildly infected COVID-19 patients. Earlier, in June 2021, Indian pharmaceutical giant Dr Reddy’s Laboratories announced the commercial launch of the anti-COVID-19 drug 2DG, approved for emergency use as an adjunct therapy to standard care of treatment.
Health Management Initiatives Propelling Demand for Geriatric Medicines in North America?
According to Rural Health Information Hub, the U.S. consists of more than 46 million older adults. In addition, rise in lifestyle diseases like obesity, well-established healthcare infrastructure, surge in geriatric population and presence of key market players are anticipated to leverage the North American geriatric medicines market.
Moreover, various clinical studies, research projects and geriatric health management initiatives are underway in North America. Thus, projections indicate a market share of nearly two-fifths and a CAGR of 5.7% throughout the forecast period.
Is Investment in Healthcare Making Asia a Lucrative Market for Geriatric Medicines?
High economic growth and the resulting increase in disposable incomes, combined with a large population in emerging countries such as China and India along with consequent investment in healthcare infrastructure are anticipated to burgeon market prospects. In addition, growing cases of neurological conditions is spurring the demand for medicines in the region.
Thus, Asia is poised to emerge as a lucrative market for geriatric medicines by capturing over 20% of the global geriatric medicines revenue. Furthermore, the region is expected to register a CAGR of 6.7% is projected assessment period 2021-2031.
An Adaptive Approach to Modern-day Research Needs
Why are Analgesic Geriatric Medicines Garnering Popularity?
The analgesic therapeutic segment is projected to capture a significant chunk of demand in the global market for geriatric medicines. Rising demand for painkillers for various chronic conditions like arthritis is anticipated to boost growth.
In addition, major drugs utilized for the geriatric population include Ibuprofen, Diclofenac, Ketorolac and Toradol have gained popularity due to their effectiveness. According to Fact.MR, the segment is projected to exhibit a CAGR of 6%, capturing over 2/5th market share, across the 2021-2031 forecast period.
Hypertension Accelerating Growth for Antihypertensive Therapeutics?
The antihypertensive therapeutics segment is projected to grow the fastest during the forecast period. Rising incidences of hypertension attributed to changing lifestyles and increased life expectancy are poised to leverage prospects for antihypertensive drugs.
Thus, the above mentioned factors are accelerating the growth of antihypertensive therapeutics. This has led to the antihypertensive therapeutics segment to register a CAGR of 6.3% during the forecast period.
Cardiovascular Ailments Treatment to Make Maximum Use of Geriatric Medicines?
According to Fact.MR’s forecast, geriatric medicines will be in most demand to treat cardiovascular ailments. A market share worth 45% has been projected for this segment across the forthcoming decade. Increasing prevalence of heart ailments is chiefly driving market growth.
Various manufacturers have launched potent cardiovascular medicines in recent years. For instance, Novartis AG published results of its Phase-III ORION 9, 10 and 11 trials for its Leqvio® (inclisiran) drug, which provides effective and sustained LDL-C reduction amongst atherosclerotic cardiovascular disease affected patients.
Prominent geriatric medicines manufacturers are emphasizing on a wide array of expansion strategies, comprising of acquisitions, new product launches and collaborations. Some prominent developments in the geriatric medicines industry as follows:
- In August 2021, Pfizer announced that it will acquire Trillium Therapeutics, a clinical stage immune oncology company. The acquisition will work towards improvising the treatments of cancer. According to Pfizer, the deal is likely to be worth US$ 2.26 billion.
- In October 2021, Merck & Co. Inc. published preliminary results of the clinical trials for its Molnupiravir anti-COVID-19 drug. As per the findings, patients administered with this anti-viral halved chances of hospitalization amongst patients exhibiting mild or moderate symptoms. Those administered with this drug showed 100% recovery
Interested to Procure The Data
|Market Size Value in 2021||USD 768 Million|
|Market Value Forecast in 2031||USD 1.5 Billion|
|Growth Rate||CAGR of 7% from 2021 to 2031|
|Historical Data Available for||2016-2020|
|Market Analysis||US$ Mn for Value & ‘000 Units for Volume|
|Key Regions Covered||
|Key Countries Covered||
|Key Segments Covered||
|Key Companies Profiled||
|Pricing||Available upon Request|
Key Segments Covered
- Analgesic Geriatric Medicines
- Anti-Hypertensive Geriatric Medicines
- Statin Geriatric Medicines
- Anti-Diabetic Geriatric Medicines
- Proton Pump Inhibitor Geriatric Medicines
- Anticoagulant Geriatric Medicines
- Anti-Psychotic Geriatric Medicines
- Anti-Depressant Geriatric Medicines
- Geriatric Medicines for Cardiovascular Ailments
- Geriatric Medicines for Arthritis
- Geriatric Medicines for Diabetes
- Geriatric Medicines for Neurological Disorders
- Geriatric Medicines for Cancer
- Geriatric Medicines for Osteoporosis
- Geriatric Medicines for Respiratory Disorders
- Geriatric Medicines for Other Conditions
- Geriatric Medicines Sales via Hospital Pharmacies
- Geriatric Medicines Sales via Retail Pharmacies
- Geriatric Medicines Sales via Online Pharmacies
- FAQs -
As of 2021, the market for geriatric medicines will reach US$ 768 Mn
The geriatric medicines industry is expected to surpass a CAGR of 7% from 2021-2031
From 2016-2020, geriatric medicines sales surged at a CAGR of 5.5%, according to Fact.MR
The geriatric medicines market is expected to reach US$ 1.5 Bn by 2031
North America is likely to surge at a CAGR of 5.7% from 2021 to 2031, with respect to geriatric medicines demand
Asia will likely by the fastest growing market, registering a CAGR of 6.7% until 2031
AstraZeneca, Merck & Co, Inc., Pfizer, Inc., Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Abbott Laboratories and Boehringer Ingelheim GmbH are some prominent geriatric medicine market players
Antihypertensive therapeutic category is expected to hold the highest share for sales, expanding at over 6.3% CAGR
Geriatric medicines for cardiovascular ailments will likely be most demanded, accounting for 45% revenue share
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.